The COVID-19 pandemic has, and continues to have, a significant effect on the lives of individuals worldwide. Published reports suggest an elevated risk of COVID-19 among patients with cancer. As such, oncologists globally have had to adapt their management of cancer patients to minimize the risk of infection, while ensuring optimal care for this population.
Individuals with underlying cardiovascular disease (CVD) may be at an increased risk of dying from COVID-19 while in hospital, according to a recent study.
Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.